Lantern Pharma (NASDAQ: LTRN) announced it will host its first live, public demonstration of its withZeta.ai multi-agentic AI co-scientist platform on April 30, 2026, with two sessions scheduled to accommodate global audiences. The event will feature a real-time, interactive demonstration led by CEO Panna Sharma, showcasing the platform’s ability to execute complex oncology research workflows by integrating clinical, molecular and scientific datasets.
The company said the platform is designed to accelerate drug discovery timelines, particularly in rare cancers, while supporting a scalable, subscription-based commercial model. WithZeta.ai is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for Lantern Pharma.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
The live demo comes as the company seeks to demonstrate the practical capabilities of its AI platform to potential subscribers. By integrating diverse datasets, withZeta.ai aims to streamline research processes that traditionally take years, potentially reducing the time and cost associated with bringing new cancer therapies to market. The subscription model could provide recurring revenue, diversifying Lantern’s income beyond its drug development pipeline.
For investors and the biomedical community, the demonstration offers a chance to assess the platform’s real-world utility. The event underscores the growing trend of AI-driven drug discovery, where machine learning tools are increasingly used to identify drug candidates, predict patient responses, and optimize clinical trial designs. Lantern’s focus on rare cancers addresses a significant unmet need, as these diseases often lack effective treatments due to limited research.
Full details of the press release are available at https://ibn.fm/wzevl. For the latest news on Lantern Pharma, visit the company’s newsroom at https://ibn.fm/LTRN.
